Glioblastoma Multiforme
Conditions
Keywords
Glioblastoma Multiforme, Zarnestra, Radiation therapy
Brief summary
The purpose of this study is to determine the efficacy by the determination of the Time To Progression (TTP) in patients with resectable GBM or non surgical GBM with a size less than 5 cm treated with the combination of ZARNESTRA plus Radiation therapy.
Interventions
DRUGZarnestra
ZARNESTRA 100 bid (phase II recommended dose defined in phase I)will be administered continuously from one week prior to start of radiation therapy until the last day of radiation therapy.
PROCEDUREstandard Radiation therapy
Radiotherapy will be focused on the initial tumour volume with a reasonable margin of safety (2 cm). A total dose of 60 Gray (Gy) will be given to the Clinical Target Volume
Sponsors
Institut Claudius Regaud
Janssen-Cilag Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have pathologically confirmed (histology or cytology), resectable or non resectable, glioblastoma multiforme with a size \< 5 cm on MRI if non resectable * Patients must be at least 7 days but no more than 2 months since surgery or biopsy. * Patients must have an ECOG Performance Status ≤ 2. * Patients must be aged 18 * Patient has signed the informed consent form
Exclusion criteria
* Patients with unresectable glioblastoma with a size \>5 cm on MRI * Patients with clinically apparent leptomeningeal metastases * Patients with uncontrolled seizures despite standard anticonvulsant therapy * Any prior systemic treatment (chemotherapy, immunotherapy, hormonal therapy) for glioblastoma multiforme * Significantly abnormal haematological status as judged by: Absolute neutrophil count (ANC) \< 1500/mm3 (1.5\*109/l) Platelet count \<100,000/mm3 (100\*109/l) * Serum bilirubin \>2 mg/dl (\>34 mmol/l) or Transaminase \>2.5x the upper limit of institutional normal or Creatinine \>1.5 mg/dl (\>132 mmol/l) * Inability to co-operate with the treatment protocol * Patients who cannot undergo imaging evaluations * Participation in an investigational drug trial in the 30 days prior to selection * Pregnant or nursing mothers. (Female patients of childbearing potential must use adequate contraception.) * Any malignancy within the past five years. Exceptions are: superficial basal cell carcinoma or non-metastatic squamous cell cancer of the skin, cervix cancer (cervical intra-epithelial neoplasia -CIN or FIGO stage 1) or prostate intra-epithelial neoplasia (PIN), biochemical relapse free for at least 3 years. * Any prior systemic chemotherapy in the past five years for any malignancy in the medical history * Any concurrent disease that in the opinion of the investigator would constitute a hazard for participating in this study * Known sensitivity to imidazole derivatives * Patients under law protection * Medical history of phlebitis or pulmonary embolism, thrombocytosis, myocardiopathy, or other relevant cardiac pathology (auricular flutter, auricular fibrillation) * Medical history of immuno-allergic pneumopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy will be assessed by the determination of the Time To Progression (TTP) in patients with resectable GBM or non surgical GBM with a size less than 5 cm treated with the combination of ZARNESTRA plus Radiation therapy | time of study |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate (RECIST and volumetric criteria) | time of study |
| Median survival, 6 month and 1 year survival rates | 6 month and 1 year |
| Safety of combination therapy of ZARNESTRA and RT, based on laboratory and clinical parameters | time of study |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORElizabeth MOYAL, Dr
Institut Claudius Regaud
Outcome results
None listed